Drug intelligence / Profile preview

ICA01TB

Development stage: Preclinical
Lead developer: iCamuno Biotherapeutics

Overview

ICA01TB is a drug candidate currently in preclinical development by Suzhou Aikailiyuan Biotechnology Co., Ltd. It is being investigated for its potential in treating B-Cell Malignant Neoplasm, with broader therapeutic areas including Immune System Diseases and Hemic and Lymphatic Diseases. The specific mechanism of action for ICA01TB is not publicly disclosed at this time.

Beyond the preview

Go deeper on ICA01TB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICA01TB.

Explore the full profile